View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 31, 2019updated 12 Jul 2022 12:27pm

Phesi launches AI-powered clinical trial investigator tool ClinSite

Phesi has launched ClinSite, a self-service, artificial intelligence (AI)-powered tool which enables biopharmaceutical companies to search for top-performing investigator sites for clinical trials in all therapeutic areas.

Phesi has launched ClinSite, a self-service, artificial intelligence (AI)-powered tool which enables biopharmaceutical companies to search for top-performing investigator sites for clinical trials in all therapeutic areas.

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

The Software as a Service (SaaS) solution ClinSite incorporates natural language processing and machine learning and was fully automated last year.

The platform incorporates data from 4.2 million physicians and nearly 600,000 investigator sites, identified from over 80,000 sources and 330,000 clinical trials in 240 countries.

Investigator sites which are selected through ClinSite in more than 250 clinical trials have enrolled participants up to 40% faster than other sites.

Phesi founder and president Gen Li said: “ClinSite isn’t just an investigator site search engine; it also updates, cleans, and structures millions of data points automatically and in real-time, for easy filtering and analysis by the users.

“Phesi’s algorithms combine data and model ’what if‘ scenarios, enabling clinical trial sponsors and designers to make well-informed and quick decisions – saving precious time and money in getting new therapies to patients.”

According to a recent survey of 761 clinical trials from Phesi’s database, it was analysed that 30% of Phase III trials experienced a delay of at least three months.

Even one such delay can have tremendous financial effects, considering recently published data estimating the median cost of a Phase III clinical trial at $19m and a per-patient cost of $44,117.

Phesi board member Steve Arlington said: “It is nearly impossible to gauge investigator site performance, one of the main reasons for poor site selection when using traditional trial planning methods.

“Using an AI-driven tool like ClinSite enables sponsors to automatically compare relevant trials and pinpoint global sites with the right expertise and proven performance for a given protocol design in any therapeutic area.”

Next year, the company also intends to launch a fully integrated module that will help trial sponsors optimise design of study protocols.

Related Companies

Free Report
img

How attractive are current investment opportunities in Europe?

Europe has been identified as one of the most favorable regions for investors, seeing high investment activity in the past year. Most of these investments have been through Debt Offering, valued at close to $700 billion. The region has provided attractive investments in a diverse set of companies. Companies who tend to major themes such Digital Media, Cloud, Artificial Intelligence, E-commerce, and Big Data are recording the highest number of deals, with Digital Media recording close to 2,000 deals. However, GlobalData’s whitepaper offers a full view of the market, analyzing less successful or attractive points of investment as well, examining statistics on Equity Offering investments and PE/VC deals. Understand how government agencies for economies around the world use GlobalData Explorer to:  
  • Track the M&A and Capital Raising volumes into their target market
  • Identify the top sectors in the target market attracting the investments
  • For any investment segment, identify the top Investors inside and outside the target economy that are already investing in the Segment
  • Assess and showcase the growth potential for various Industries in the target economy
Don’t miss out on key market insights that can help optimize your next investment – read the report now.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena